This week, Wiley appointed Prof Cedric Hermans as the new Editor-in-Chief, of Haemophilia, the official journal of EAHAD. Prof Hermans, EAHAD’s Past-President, replaces Prof Michael Makris and Dr Craig Kessler, who step down from their editorial posts this month and at the end of the year, respectively.
For the past three decades, haemophilia A and B patients have been treated using FVIII and FIX replacement concentrates. These therapies are well known to clinicians and patients.
A promising new era has now begun in the treatment of haemophilia and rare bleeding disorders. A series of novel, non-replacement therapies are becoming available, which may significantly impact the clinical care and quality of life of patients. The European Association for Haemophilia and Allied Disorders (EAHAD) and the European Haemophilia Consortium (EHC) welcome all novel therapies that have a meaningful impact on patients’ treatment, care and quality of life.
